Although it’s trying to keep quiet about its product, a medical device startup developing a new treatment for obesity revealed this week it’s in the middle of raising $5.5 million. According to a recently filed U.S. Securities and Exchange Commission document, Vibrynt Inc. has raised half of a $5.5 million offering from five investors. Vibrynt’s website provides little information about the device and says only that the company is “dedicated to creating minimally invasive therapies for patients suffering from morbid obesity.” A phone call to CEO Beverly Hess was not immediately returned.
